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Background: Although several studies suggest that stromal fibroblasts mediate treatment resistance in several
cancer types, little is known about how tumor-associated astrocytes modulate the treatment response in brain
tumors. Since traditionally used metabolic assays do not distinguish metabolic activity between stromal and tumor
cells, and since 2-dimensional co-culture system does not recreate the formidable complexity of the microenvironment
within 3-dimensional structures such as solid tumor tissue, we instead established a glioblastoma (GBM) cell-specific
bioluminescent assay for direct measurements of tumor cell viability in the treatment of clinical relevant drugs.
Methods: Using lentiviral transfection, we established a panel of human GBM cell lines constitutively expressing a
fusion transgene encoding luciferase and the enhanced green fluorescence protein (eGFP). We then initiated
co-cultures with immortalized astrocytes, TNC-1, and the eGFP/Luc GBM cell lines. Next, we treated all eGFP/Luc
GBM cell lines with Temozolomide (TMZ) or Doxorubicin, comparing co-cultures of glioblastoma (GBM) cells and
TNC-1 astrocytes with mono-cultures of eGFP/Luc GBM cells. Cell viability was quantitated by measuring the
luciferase expression.
Results: Titration experiments demonstrated that luciferase expression was proportional to the number of eGFP/
Luc GBM cells, whereas it was not influenced by the number of TNC-1 cells present. Notably, the presence of
TNC-1 astrocytes mediated significantly higher cell survival after TMZ treatment in the U251, C6, A172 cell lines as
well as the in vivo propagated primary GBM tumor cell line (P3). Moreover, TNC-1 astrocytes mediated significantly
higher survival after Doxorubicin treatment in the U251, and LN18 glioma cell lines.
Conclusion: Glioma cell-specific bioluminescent assay is a reliable tool for assessment of cell viability in the brain tumor
cell compartment following drug treatment. Moreover, we have applied this assay to demonstrate that astrocytes can
modulate chemo sensitivity of GBM tumor cells. These effects varied both with the cell line and cytotoxic drug that
were used, suggesting that several mechanisms may be involved.
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Malignant tumors of the brain, in particular glioblastoma
(GBM) represent a major unsolved clinical challenge [1].
Although the addition of radiotherapy and chemotherapy
modestly prolong survival, gliomas are inherently resistant
to these treatments, and the prognosis remains poor.
All tumors eventually recur and median survival is about
14.6 months [2].
Although GBM stem cells have been implicated in brain
tumorigenesis [3,4], studies suggest that other mecha-
nisms are involved as well [5,6]. In other cancer types,
studies clearly show that tumor-stroma interactions
regulate multiple aspects of tumor biology, including
tumor cell proliferation, invasion and drug resistance
[7-9]. Stromal cells associated with malignant brain tu-
mors include glial cells, endothelial cells, pericytes, im-
mune cells and neurons, among which glial cells are the
most abundant cell type in the brain [10]. As main sub-
population of glial cells, astrocytes have been shown to
upregulate survival genes in brain metastatic tumor cells
from melanoma and breast cancers, thereby mediating
chemoresistance [11,12]. However, little is known whether
astrocytes mediate similar effects in GBMs, and how as-
trocytes react in response to chemotherapy.
Previously, a tumor cell-specific platform has been in-
troduced to study stroma-induced changes in sensitivity
to anti-neoplastic drugs in various cancers using a 2-
dimensional (2-D) co-culture system [13]. Although
this is an extremely valuable tool that allows for high-
throughput experiments, it does not recreate the for-
midable complexity of the microenvironment within
3-dimensiona (3-D) structures such as solid tumor tissue.
Multicellular spheroids are 3-D structures that more ac-
curately reflect the complex microenvironment in situ,
compared to cells growing as monolayers. Notably, glioma
spheroids initiated from human biopsies or glioma cell
lines have been commonly used to study brain tumor biol-
ogy in matrigel, collagen gels and in medium [14-16]. In
this study, we established a 3-D model with floating co-
culture spheroids of bioluminescent GBM tumor cells and
non-luminescent rat astrocytic cells, as well as spheroid
cultures of bioluminescent GBM tumor cells only. This
tumor cell-specific bioluminescence allowed us to study
how the presence of astrocytic cells modulated the re-




The collection of tumor tissue from patients was ap-
proved by the Regional Ethics Committee at Haukeland
University Hospital (Project number 013.09; Bergen,
Norway). All patients signed informed written consent.The protocol was approved by the Committee on the
Ethics of Animal Experiments of the University of Bergen
(Bergen, Norway).Cell culture and reagents
HF66 cells were established at Henry Ford Midwest
Neuro-Oncology Center, Detroit, MI [17]; A172, U251,
LN18, C6, TNC-1 were purchased from the American
Tissue Culture Collection (ATCC; Manassas, VA, USA).
All the cells were cultured in Dulbeccos’ modified Eagles
medium (Sigma-Aldrich, St. Louis, MO, USA) containing
10% fetal bovine serum, supplemented with non-essential
amino acids, 100 U/ml Penicillin/Streptomycin, 400 μM
L-glutamine, all from Cambrex (Cambrex, East Rutherford,
NJ, USA). P3 GBM cells were taken and cultured from a
patient biopsy. All cell lines were maintained at 37°C in a
5% CO2-humidified atmosphere. Temozolomide (TMZ)
was purchased from Tocris Bioscience and dissolved in
Dimethyl Sulfoxide. Doxorubicin was purchased from
Pharmacia & Upjohn and dissolved in sterile water.Lentiviral vector production and infection of cells by
lentiviral vectors
The packaging plasmid psPAX.2 and enveloping plasmid
pMD2.G were kindly provided by Dr. Didier Trono's la-
boratory (CMU, Geneva, Switzerland). The lentiviral eGFP/
Luciferase (Luc) vector and the viral infection protocol
were kindly provided by Irving Weissman’s laboratory
(Stanford University, USA) [18]. Lentivirus was produced
by BBS/CaCl2 mediated triple-transfection of 293FT cells
with psPAX.2, pMD2.G, and eGFP/Luc vectors. Lentiviral
particles were harvested 48 h and 72 h post-transfection,
and were subsequently sterile filtered. Viral infection was
performed by centrifugation of cells at 2225 rpm for 90 mi-
nutes at room temperature in the presence of 10 μg/mL
polybrene (Sigma-Aldrich). The infected tumor cells
were kept in culture and expanded for late purification
by fluorescence-activated cell sorting.Fluorescence-activated cell sorting
Lentivirally infected A172, U251, LN18, HF66, C6 and
P3 tumor cells harboring eGFP and luciferase were tryp-
sinized and washed with ice-cold FACS buffer (PBS with
2% FBS). The cell suspension was then centrifuged at a
speed of 300 G for 5 min (4°C). The cell pellets were re-
suspended in FACS buffer and then filtered through a
40-μm cell strainer in order to remove any clumping
cells before sorting. The cells were sorted using a cell
sorter (FACS Aria SORP, BD Biosciences, Erembodegem,
Belgium) on the basis of single cell viability and eGFP
expression. The separation was confirmed by fluorescence
microscopy (Nikon ellipse 2000, Nikon, Japan).
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Trypsinized eGFP/Luc GBM cells were seeded into each
well of a 96 well plate, either non-transparent (Tomtec
plastics KFT, Hungary) or transparent V-shape well plates
(NUNC, Thermo, MA, USA) in the presence or absence
of pre-plated TNC-1 cell, with 100 μl culture medium
containing concentration of 1.74 μg/mL methylcellulose
(Sigma-Aldrich). Subsequently, the 96-well plates were
spun down at 756 G at room temperature for 15 minutes
in order to let cells form an aggregate in the well. The
plates were then cultured in a standard tissue culture in-
cubator with 5% CO2 in air and 100% relative humidity at
37°C. Spheroids derived from the mixture of 8000 eGFP/
Luc GBM cells and 5000 TNC-1 cells and 8000 eGFP/Luc
GBM cells only were chosen in the MTS assay and
Bioluminescence assay. Spheroids were photographed
at × 4 magnification using the BD Pathway Bioimager
(BD Pathway 855, BD Biosciences, CA, USA).
MTS assay
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay was car-
ried out according to a previously described method
with slight modifications [19]. Briefly, after culturing the
spheroids in the incubator for 2 days, different concen-
trations of TMZ were added to the spheroids, depend-
ing on the IC50 dose for the cell lines. After incubating
with TMZ for 5 days, the MTS substrate (Promega, CA,
USA) was added to each well. Following 3 hours of in-
cubation, the absorbance was analyzed at 490 nm on a
spectrophotometer (Asys UVM 340, Biochrom, MA, USA).
The experiments were performed 3 times.
Spheroids dissociation and flow cytometry
The spheroids that were treated by a serial diluted con-
centration of TMZ in MTS and bioluminescence assay
groups were collected respectively and washed in 1×
phosphate buffered saline following a serial trypsiniza-
tion to obtain single cell suspension. Cells were then an-
alyzed by Accuri C6 (BD Biosciences, Erembodegem,
Belgium), in which eGFP/Luc positive tumor cells were
counted.
Bioluminescence assay
Bioluminescence assay experiments were conducted both
on spheroids treated by TMZ and on spheroids treated
by Doxorubicin, modified after a previously described
method [13]. Briefly, after culturing pre-made spheroids
in the 96-wells plate for 2 days, different concentrations
of TMZ/Doxorubicin were added into each well with a
total volume of 100 μl medium. After 5 days incubation
of the spheroids with TMZ/Doxorubicin, the luciferinsubstrate was added to the wells and luciferase activity
was then measured at different time intervals using a
PerkinElmer Victor 3 Multilabel plate reader (PerkinElmer,
CA, USA). Luciferin substrate solution was prepared
by dissolving firefly diluent (Biosynth, Switzerland) in
ddH2O supplemented with 100 nM/L Adenosine 5’Tri-
phosphate (ATP, Sigma-Aldrich) to a stock concentration
of 3×104 μg/ml and their final concentration in each well
was 375 μg/mL. All experiments were performed 3 times.Statistics
We assessed the correlation between cell number and
bioluminescence by estimating the coefficient of deter-
mination (R2). Growth curves were analyzed using the
two-way ANOVA measures, and p-values < 0.05 were
considered significant.Results
Bioluminescence intensity of spheroids is reproducible
and proportional with the number of tumor cells
Spheroids of GBM tumor cells only were initiated by
seeding increasing numbers of tumor cells into individual
wells of a 96-well plate (Figure 1A). Notably, comparison
of different tumor cell numbers and bioluminescence
values of the spheroids demonstrated a linear relationship
(R2 = 0.9993 for U251 cells and R2 = 0.9987 for A172 cells)
(Figure 1B and C). Thus, bioluminescence intensities were
proportional to the number of tumor cells, demonstrating
that bioluminescent could be used as a highly reliable
measurement to quantitate the cell number.Tumor cell specific bioluminescence intensity is
independent of the size of the TNC-1 stromal cell
compartment
In order to investigate whether the number of stromal
cells impacted on the bioluminescent signal detected
from the tumor cell compartment, we established co-
culture spheroids. By mixing a varying number of
eGFP/Luc A172 tumor cells with a varying number of
stromal TNC-1 cells, we obtained spheroids with a
spatial distribution of the eGFP signal with different ra-
tios of glial stromal cells and glioma cells (Figure 2A).
The most homogeneous spheroids resulted from mix-
ing 8000 tumor cells with 5000 TNC-1 cells, and these
were used in subsequent treatent experiments. More-
over, bioluminescence intensities were measured from
spheroids, mixing 8000 eGFP/Luc A172 tumor cells
with a varying number of TNC-1 cells (0, 2000, 4000,
6000, 8000, 10000, 20000, 30000, 40000 and 50000),
and demonstrated that the number of TNC-1 cells did
not influence the quantification of tumor cell numbers
(Figure 2B).
Figure 1 Bioluminescence expression is proportional to the number of tumor cells in spheroids formation. A: eGFP expressing glioma
spheroids initiated from an increasing number of 172 glioma cells (500, 1000, 2000, 4000, 8000, 16000, 32000, 64000, 96000, 128000) per well.
B and C: Bioluminescence measurements for increasing cell numbers of U251 and A172 glioma cells demonstrated a linear relationship
(R2 = 0.9993 for U251 cells and R2 = 0.9987 for A172 cells).
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demonstrates reduction in cell survival rates not
detected by the MTS assay (p < 0.05)
Next, cell numbers in GFP/Luc LN18 glioma cells treated
with different doses of TMZ for five days were counted
using flow cytometry. As expected, we observed a dose-
dependent reduction in cell numbers reflecting cytotox-
icity. We then compared measurements by the luciferase
assay with the commonly used MTS assay on mono-
culture and co-culture spheroids following treatment with
different concentrations of TMZ. Results from theseFigure 2 TNC-1 cells have no influence on bioluminescence expressio
tumor cells (500, 800, 1600, 3200, 6400, 8000, 16000, 32000, 48000 and 640
4000, 56000, 810000, 210000, 200000, 30000 and 40000) respectively, initiat
co-cultured with TNC-1 with an increasing cell numbers (0, 500, 1000, 2000
TNC-1 has no influence on bioluminescence value changes of A172 tumor
in the co-culture spheroids.experiments demonstrated that tumor cell survival
measured by both MTS assay and bioluminescence
assay on mono-culture spheroids treated with different
doses of TMZ showed dose-dependent cell survival
rates as the reduction in cell numbers as determined
by flow cytometry (Figure 3A and B). However, on co-
culture spheroids treated with different doses of TMZ,
MTS assay showed no dose-dependent cell survival
rates as reflected the reduction in cell numbers as de-
termined by flow cytometry, whereas bioluminescence
assay showed significant dose-dependent cell survivaln of tumor cells. A: mixing a varying number of A172 eGFP/Luc
00) with a varying number of stromal TNC-1 cells (100, 500, 1000, 2000,
e homogeneous spheroids. B: 8000 A172 eGFP/Luc tumor cells were
, 4000, 6000, 8000, 10000, 200000, 30000 and 40000) demonstrated
cells indicating bioluminescence intensity is proportional to tumor cells
Figure 3 (See legend on next page.)
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Figure 3 Cell viability measured by bioluminescence versus the MTS assay after treatment with TMZ. A and B: LN18 eGFP positive cells
on mono-culture spheroids treated with TMZ at doses as indicated were counted by flow cytometry, and compared to measurements by MTS
assay and bioluminescence assay, respectively. C and D: LN18 eGFP positive cells on co-culture spheroids with TNC-1 cells treated with TMZ at
doses as indicated were counted by flow cytometry, and compared to measurements by MTS assay and bioluminescence assay, respectively.
E, F, G and H: Comparison of MTS with bioluminescence intensity measurements in the LN18, A172, U251 and C6 glioma cell lines co-cultured
with TNC-1 cells after treatment with TMZ at doses as indicated.
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mined by flow cytometry (Figure 3C and D). Moreover,
except for LN18, in the A172, U251 and C6 eGFP/Luc gli-
oma cell lines we observed a consistent dose-dependent
reduction in bioluminescence assay after TMZ treatment,
whereas MTS showed no significant changes for any of
these cell lines (Figure 3E, F, G and H).
TNC-1 cells modulate sensitivity to TMZ in glioma cell
lines
We then tested the response of tumor cells to TMZ in the
presence or absence of TNC-1 cells. Bioluminescence
based quantification demonstrated that TNC-1 cells atten-
uated the response of the U251, C6, P3 and A172 eGFP/
Luc glioma cell lines to TMZ at the concentration of
20–320 μM for U251; 200–1000 μM for C6 and A172;
100–500 μM for P3 (p < 0.05, Figure 4A, B, C and D). For
the LN18 and HF66 glioma cell lines however, the TNC-1
cell line did not impact on chemosensitivity (Figure 4E
and F) at the concentration of 200–1000 μM.Figure 4 TNC-1 cells modulate sensitivity of TMZ to GBM tumor cells.
A172 tumor cells to TMZ treatment respectively. E and F: The cell survival o
or absence of TNC-1.TNC-1 cells modulate sensitivity to Doxorubicin in glioma
cell lines
Since Doxorubicin has shown efficacy in some studies
against glioma using local delivery [20], we also tested
whether the sensitivity of GBM cells to Doxorubicin was
modulated by the presence of TNC-1 astrocytic cells.
Again, the presence of TNC-1 attenuated the response
of U251 and LN18 tumor cells to Doxorubicin as mea-
sured by bioluminescence intensity (Figure 5A and B),
whereas no effects were seen for the C6, P3 and A172
glioma cell lines (Figure 5D, E and F). The effect of
Doxorubicin at the concentration of 0.5, 1 and 2 μM
were significantly attenuated by TNC-1 (p < 0.05) in the
U251 and LN18 glioma cell lines. HF66 showed higher
cell survival in the presence of TNC-1 cells although this
was not significant except at a dose of 1 μM Doxorubi-
cin (p < 0.05) (Figure 5C). Furthermore, with increasing
concentrations of Doxorubicin more A172 cells were
eliminated in the presence of TNC-1 compared to spher-
oids of tumor cells only.A, B, C and D: TNC-1 attenuated the response of U251, C6, P3 and
f LN18 and HF66 to TMZ was not significantly different in the presence
Figure 5 TNC-1 cells modulate the sensitivity of Doxorubicin to GBM tumor cells. A, B and C: TNC-1 attenuated the response of U251 and
LN18 to Doxorubicin at the concentration of 0.5, 1 and 2 μM. HF66 seemed to be protected by TNC-1 at different concentration of doxorubicin,
but not significant (p > 0.05) except at the concentration of 1 μM (p < 0.05). D, E and F: TNC1 has no effect on C6, A172 and P3 tumor cells.
However, with increasing concentrations of TMZ more A172 cells were eliminated in the presence of TNC-1 compared to spheroids of tumor
cells only.
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Currently, little is known about the role of astrocytes in
brain tumor in response to chemotherapy. Few models
for drug testing take into account the role of tumor-
astrocyte interactions in modulating treatment response
in brain tumors for instance, how the presence of astro-
cytic cells modulated the chemo-response in GBMs, the
most malignant brain tumors in human with short sur-
vivals. On the contrary, traditional chemotherapeutics
testing in vitro is usually performed in pure tumor cell
cultures. Moreover, these model systems usually involve
monolayers and suspension tumor cell cultures. In this
context, cells are growing on the surface of artificial
plastic or glass substrate and in contact with other cells
only at their periphery. Apparently, these models do not
reflect the multicellular microenvironment found in the
body. Although, expensive animal models have been ac-
cepted to use in drug testing by researchers, the best pre-
clinical model should be relatively inexpensive, amenable
to high-throughput screening, and most importantly, re-
flect human tumor biology as closely as possible. Previous
studies have shown that 3-D model systems such as spher-
oid models reflect the biology of GBM closer than 2-D
model systems such as monolayer cell cultures [21,22]. In
order to address these limitations, in the current studies,
we established a 3-D co-culture model comprising bothTNC-1 astrocytic cells and different eGFP-luciferase ex-
pressing glioma cell lines. This model provides a standard-
ized method for obtaining multiple cellular spheroids of
equal size with a reproducible number of cells in a high-
throughput manner.
MTS assay is well established and widely accepted for
assessing cell viability [23]. In this study however, compari-
son of the MTS and bioluminescence assay, demonstrated
that although both MTS assay and bioluminescence assay
are reliable to measure the cell survival on mono-culture
spheroids, measurement of bioluminescence intensity
reflected alterations in cell survival more accurately on
co-culture spheroid systems. A likely explanation for
this finding is that the TNC-1 stromal cells contribute
to the overall metabolic activity which is measured in
the MTS assay, whereas the luciferase expression is re-
stricted to the tumor cell compartment.
3-D spheroid systems provide a rapid, reproducible and
high-throughput screen assay for the effective triaging of
drug candidates prior to in vivo studies [24]. Furthermore,
TMZ is now established as a primary treatment for GBM
together with radiotherapy and surgery [25,26]. Doxorubi-
cin has been reported to significantly improve survival
when used for treatment of brain tumor in a 9 L glioma
animal model by local delivery, and the chemo sensitivity
in the animal after systemic injection was dramatically
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[20]. Despite this, the effects of Doxorubicin on patients
have been generally disappointing. Thus we used the 3-D
model to investigate how astrocytes impact on glioma cell
sensitivity to TMZ and Doxorubicin. Strikingly, we found
that the presence of TNC-1 astrocytic cells attenuated the
anti-glioma efficacy of TMZ as well as Doxorubicin in sev-
eral glioma cell lines. GBM tumor cells behaved differently
in response to TMZ and Doxorubicin in the co-culture
than when the tumor cells were cultured alone. In recent
years, cancer associated fibroblast (CAF) mediated drug
resistance has been extensively studied. Previously,
McMillin et al. reported, using their co-culture 2-D
model that tumor cells responded heterogeneously de-
pending on the tumor type, accessory cells and cytotoxic
reagents that were used [13]. Moreover, their molecular
profiling studies in a multiple myeloma cell line interact-
ing with stroma, suggested activation of pathways related
to drug resistance. CAFs have been shown to protect
breast cancer cells against apoptosis induced by Doxorubi-
cin and the PARP-1 inhibitor ABT-888 [27]. Using a com-
bined experimental model and theoretical approach, Falch
et al. showed CAFs contributed to tumor growth and
treatment resistance in melanoma [28]. In the normal
state, as the most abundant subpopulation of glial cells,
the roles of astrocytes in the brain overlap with the func-
tions of fibroblasts in other organs, such as providing
structural support. Thus, it is conceivable that astrocytes
and fibroblasts also have similar roles in tumor progres-
sion. Ultimately, in light of our findings that TNC-1 medi-
ated TMZ and Doxorubicin resistance in various GBM
cell lines, we believe that the interaction of astrocytes and
tumor cells can fundamentally affect both brain tumor
growth and treatment and should be an important focus
for future brain tumor research.Conclusions
We constructed a 3-D model, containing both the tumor
and astrocyte cell compartments. In this model we co-
cultured luciferase expressing tumor cells with luciferase-
negative TNC-1 cells, so that the viability of tumor cells
could be distinguished from accessory cells. Using this
model, we demonstrate that TNC-1 cells may impact on
sensitivity to TMZ and Doxorubicin in a cell line spe-
cific manner. We believe that co-culture 3-D spheroids
could act as a preclinical high-throughput drug-screening
model which may potentially reduce the cost for extensive
testing in vivo. Moreover, this model may provide a
valuable tool for investigating mechanisms underlying
astrocytes-induced drug resistance.Competing interests
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